Marinus Pharmaceuticals Stock Current Valuation
| MRNS Stock | USD 0.32 0.01 3.23% |
Valuation analysis of Marinus Pharmaceuticals helps investors to measure Marinus Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 602.7 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (4.80) in 2024. Fundamental drivers impacting Marinus Pharmaceuticals' valuation include:
Price Book 3.1717 | Enterprise Value 31.6 M | Enterprise Value Ebitda (34.47) | Price Sales 0.5877 | Enterprise Value Revenue 1.0041 |
Undervalued
Today
Please note that Marinus Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Marinus Pharmaceuticals is based on 3 months time horizon. Increasing Marinus Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Marinus stock is determined by what a typical buyer is willing to pay for full or partial control of Marinus Pharmaceuticals. Since Marinus Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Marinus Stock. However, Marinus Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.32 | Real 0.0 | Target 20.9 | Hype 0.0 | Naive 0.65 |
The intrinsic value of Marinus Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Marinus Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Marinus Pharmaceuticals helps investors to forecast how Marinus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Marinus Pharmaceuticals more accurately as focusing exclusively on Marinus Pharmaceuticals' fundamentals will not take into account other important factors: Marinus Pharmaceuticals Company Current Valuation Analysis
Marinus Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Marinus Pharmaceuticals Current Valuation | 31.59 M |
Most of Marinus Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marinus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Marinus Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Marinus Pharmaceuticals is extremely important. It helps to project a fair market value of Marinus Stock properly, considering its historical fundamentals such as Current Valuation. Since Marinus Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Marinus Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Marinus Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Marinus Pharmaceuticals has a Current Valuation of 31.59 M. This is 99.78% lower than that of the Pharmaceuticals sector and 99.32% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.81% higher than that of the company.
Marinus Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marinus Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marinus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Marinus Pharmaceuticals by comparing valuation metrics of similar companies.Marinus Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Marinus Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Marinus Pharmaceuticals from analyzing Marinus Pharmaceuticals' financial statements. These drivers represent accounts that assess Marinus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Marinus Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 117.4M | 117.7M | 436.0M | 155.5M | 584.2M | 613.4M | |
| Enterprise Value | 49.6M | 27.3M | 353.8M | (12.4M) | 574.0M | 602.7M |
Marinus Fundamentals
| Return On Equity | -29.87 | ||||
| Return On Asset | -0.58 | ||||
| Operating Margin | (3.76) % | ||||
| Current Valuation | 31.59 M | ||||
| Shares Outstanding | 55.19 M | ||||
| Shares Owned By Insiders | 10.94 % | ||||
| Shares Owned By Institutions | 83.03 % | ||||
| Number Of Shares Shorted | 5.66 M | ||||
| Price To Earning | (4.80) X | ||||
| Price To Book | 3.17 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 30.99 M | ||||
| Gross Profit | (55.94 M) | ||||
| EBITDA | (125.5 M) | ||||
| Net Income | (141.41 M) | ||||
| Cash And Equivalents | 168.25 M | ||||
| Cash Per Share | 4.52 X | ||||
| Total Debt | 110.36 M | ||||
| Debt To Equity | 0.88 % | ||||
| Current Ratio | 8.41 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (118 M) | ||||
| Short Ratio | 1.09 X | ||||
| Earnings Per Share | (2.47) X | ||||
| Target Price | 1.47 | ||||
| Number Of Employees | 165 | ||||
| Beta | 1.26 | ||||
| Market Capitalization | 17.79 M | ||||
| Total Asset | 170.91 M | ||||
| Retained Earnings | (571.93 M) | ||||
| Working Capital | 124.62 M | ||||
| Current Asset | 57.77 M | ||||
| Current Liabilities | 7.43 M | ||||
| Net Asset | 170.91 M |
About Marinus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marinus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marinus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marinus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Marinus Stock Analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.